“The flu vaccine needs to change every year because the virus is constantly mutating,” Jacob Yount, assistant professor of microbial infection and immunity at Ohio State University and senior author of the study, said in a statement. “What we’re doing is targeting a more fundamental process that is not specific to any particular strain of the virus.”
The method capitalizes on a protein — IFITM3 — that is known to be effective against all strains of influenza. Levels of IFITM3 can be raised by suppressing a different protein, called NEDD4. This leads to an accumulation of the virus-fighting IFITM3 in the cells. Although the researchers are still working to determine how and when to best get rid of NEDD4, the method has shown promise in both mouse and human cells.
More articles on infection control:
CDC report outlines new approach for HAI reduction
Legionnaire’s bacteria discovered in GlaxoSmithKline plant
FDA releases new guidance for cleaning ‘unsafe’ scopes
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
